Urologie pro praxi 1/2020
Current treatment management of non-metastatic castration-resistant prostate cancer
Prostate cancer is the most common cancer that affects men (except of skin tumors). Although most cases of prostate cancer are diagnosed and treated at an early stage, some patients already have primary dissemination or metastatic spread during therapy. Current research has led to the expansion of the treatment armamentarium for patients with prostate cancer. Therapeutic options in patients with castration-resistant prostate cancer aim to prolong survival with minimal development of complications and with the highest possible quality of life.
Keywords: castration-resistant prostate cancer, apalutamid, enzalutamid.
